Non-‘classical’ MEKs: A review of MEK3-7 inhibitors

Ada J. Kwong, Karl A. Scheidt*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations

Abstract

The MAPK pathways are an enduring area of interest due to their essential roles in cell processes. Increased expression and activity can lead to a multitude of diseases, sparking research efforts in developing inhibitors against these kinases. Though great strides have been made in developing MEK1/2 inhibitors, there is a notable lack of chemical probes for MEK3-7, given their central role in stimuli response, cell growth, and development. This review summarizes the progress that has been made on developing small molecule probes for MEK3-7, the specific disease states in which they have been studied, and their potential to become novel therapeutics.

Original languageEnglish (US)
Article number127203
JournalBioorganic and Medicinal Chemistry Letters
Volume30
Issue number13
DOIs
StatePublished - Jul 1 2020

Funding

Funding for these efforts has been provided by the National Cancer Institute of the National Institutes of Health (NCI; R01CA188015) and Northwestern. AJK is supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number T32GM105538. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors thank Meghan Orr (NU), Dalton Kim (NU), and David Burke (NU) for manuscript proofreading. Funding for these efforts has been provided by the National Cancer Institute of the National Institutes of Health (NCI; R01CA188015 ) and Northwestern. AJK is supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number T32GM105538 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health . The authors thank Meghan Orr (NU), Dalton Kim (NU), and David Burke (NU) for manuscript proofreading.

Keywords

  • Drug discovery
  • Kinases
  • Mitogen-activated protein kinases
  • Small molecule inhibitors
  • Structure-activity relationships

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine
  • Molecular Biology
  • Biochemistry
  • Clinical Biochemistry
  • Pharmaceutical Science
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Non-‘classical’ MEKs: A review of MEK3-7 inhibitors'. Together they form a unique fingerprint.

Cite this